Literature DB >> 23234187

The HPV infection in males: an update.

G Giraldi1, E De Luca d'Alessandro.   

Abstract

The role of Human papillomavirus (HPV) in malignant and non-malignant genital diseases in females is well known and the corresponding epidemiological burden has been widely described, in males instead, less is known about the role of the virus in anal, penile and head and neck cancer, and the burden of malignant and non-malignant HPV-related diseases. There are many types of HPV that can infect the epithelium: some types can cause genital warts (low risk genotype), other types (high risk genotypes) can cause cancers of the penis, anus or oropharynx. Relative to females, males tend to be less knowledgeable about the infection: some may view its consequences as less likely and severe for themselves than for females, and thus could perceive vaccination as unnecessary. Including boys in the vaccination program generally exceeded conventional thresholds of good value for money, even under favorable conditions of vaccine protection and health benefits; however, uncertainty still exists in many areas that can either strengthen or attenuate the findings achieved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23234187

Source DB:  PubMed          Journal:  Ann Ig        ISSN: 1120-9135


  3 in total

1.  Parental attitudes towards male human papillomavirus vaccination: a pan-European cross-sectional survey.

Authors:  Gitte Lee Mortensen; Marjorie Adam; Laïla Idtaleb
Journal:  BMC Public Health       Date:  2015-07-08       Impact factor: 3.295

2.  The Genotype of Human Papillomavirus and Associated Factors Among High Risk Males in Shanghai, China: A Molecular Epidemiology Study.

Authors:  Chengzhong Zhang; Chao Zhang; Jie Huang; Weimin Shi
Journal:  Med Sci Monit       Date:  2018-02-14

3.  Risk factors and negative consequences of patient's delay for penile carcinoma.

Authors:  Wen Gao; Le-bin Song; Jie Yang; Ning-hong Song; Xin-feng Wu; Ning-jing Song; Di Qiao; Chen Chen; Jia-yi Zhang; Zeng-jun Wang
Journal:  World J Surg Oncol       Date:  2016-04-27       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.